- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03165513
Dialogue to Empower Traditional and Faith Healers to Deliver mhGAP-IG Adapted Psychosocial Interventions in Kenya (Dialogue)
May 23, 2017 updated by: Africa Mental Health Foundation
Dialogue to Empower, Supervise, Support and Include the Traditional and Faith Healers to Deliver Evidence-based mhGAP-IG Adapted Psychosocial Interventions to Reduce Treatment Gap in Kenya
The project aimed to create a dialogue between the informal sector (traditional and faith healers) and the formal sector (trained health care workers) in order to increase synergy and communication between the two systems, by minimizing any harmful practices and enhancing complementary practices.
The informal sector will also be trained on how to use WHO mhGAP-IG component on depression for routine screening in order to ameliorate functional and social outcomes and refer complicated cases to the formal sector for biological interventions
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study seeks to empower, supervise, support and include the informal traditional and faith healers to deliver evidence-based mhGAP-IG adapted psychosocial interventions to reduce mental health treatment gap in Kenya.
This will be achieved through establishing a dialogue and collaboration between the formal and the informal sector and training the informal sector on the use of mental health Gap Action Programme Intervention Guideline (mhGAP-IG) to identify and manage depression.
It will take place in Makueni County among 100 randomly selected TH/FH.
A descriptive (prospective cohort) study will be used to determine the impact of training TH/FH on the use of mhGAP-IG in the identification and management of depression.
A mental health specialist will also determine the accuracy of diagnosis made by the informal sector using randomly selected patients (true positives and true negatives for depression) by an independent person.
Moreover, patients identified to have depression will be followed up at 6 and 12 weeks to assess their health outcomes using BECKs Depression Inventory Scale, Suicidality Scale and WHO quality of life.
Study Type
Interventional
Enrollment (Actual)
4081
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Traditional and faith healers residing in Kibwezi West constituency
- Traditional and faith healers who are willing to participate in the study.
- Traditional and faith healers' patients' above 18 years who agree to participate in the study
Exclusion Criteria:
- Traditional and faith healers not residing in Kibwezi West constituency
- Traditional and faith healers who are not willing to participate in the study.
- Traditional and faith healers' patients' above 18 years who do not agree to sign an informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
mhGAP-IG psychosocial intervention
|
psychosocial interventions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depression symptoms on the Becks Depression Inventory Scale
Time Frame: Baseline, 6 weeks and 12 weeks
|
Changes in depression scores (over time) on the Becks Depression Inventory Scale
|
Baseline, 6 weeks and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life outcomes on the WHO Quality of Life-BREF (WHOQOL-BREF)
Time Frame: baseline, 6 weeks and 12 weeks
|
Changes in quality of life domains using WHO Quality of Life-BREF (WHOQOL-BREF)
|
baseline, 6 weeks and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Christine W Musyimi, MSc, Africa Mental Health Foundation
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2014
Primary Completion (Actual)
March 20, 2015
Study Completion (Actual)
March 20, 2015
Study Registration Dates
First Submitted
May 22, 2017
First Submitted That Met QC Criteria
May 23, 2017
First Posted (Actual)
May 24, 2017
Study Record Updates
Last Update Posted (Actual)
May 24, 2017
Last Update Submitted That Met QC Criteria
May 23, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P602/12/2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Deidentified data will be made available to the researchers on request through the principal investigator.
A data request form available at AMHF will be used to make the request
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on mhGAP-IG
-
Pakistan Institute of Living and LearningNot yet recruiting
-
Norwegian Center for Violence and Traumatic Stress...Norwegian Institute of Public Health; University of Bergen; Norwegian University... and other collaboratorsRecruitingChild Abuse | Child Development | Mental Health Issue | Stigma, SocialNorway
-
Africa Mental Health FoundationUnknown
-
University Hospital, Basel, SwitzerlandSolidarMedRecruitingAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateLesotho
-
Massachusetts General HospitalNational Cancer Institute (NCI); Mayo Clinic; Washington University School of... and other collaboratorsRecruiting
-
Academy of Therapeutic Sciences, TurkeyCompletedPost Traumatic Stress DisorderTurkey
-
GWT-TUD GmbHMiltenyi Biomedicine GmbHTerminated
-
George Washington UniversityCompletedDepression | Psychosis | StigmatizationNepal
-
European Institute of OncologyIstituto Nazionale Tumori IRCCS - Fondazione G. PascaleRecruitingProstate CancerItaly
-
The Cleveland ClinicCompletedHypogammaglobulinemiaUnited States